Leptin及Ki-67在局部晚期乳腺癌新辅助化疗中的研究进展

乳腺癌的发生、发展与细胞的增殖密切相关。Leptin是一种多功能神经内分泌肽类激素，能促进细胞增殖和分化，与乳腺肿瘤的发生密切相关。乳腺癌患者化疗前血清Leptin水平高于化疗后，化疗后Leptin的降低对乳腺癌预后具有预测作用。细胞增殖核抗原Ki-67的表达与经典的乳腺癌预后指标密切相关，对新辅助化疗效果的评估及临床预后判定具有重要意义。但leptin与Ki-67对局部晚期乳腺癌（LABC）患者新辅助化疗相关性研究较少，该文主要针对leptin与Ki-67在LABC新辅助化疗中的作用作一综述。

Advances in Leptin and Ki-67 in neoadjuvant chemotherapy for locally advanced breast cancer

The occurrence and development of breast cancer are closely related to cell proliferation. Leptin is a multifunctional neuroendocrine peptide hormone, which can promote cell proliferation and differentiation, and is closely related to the occurrence of breast cancer. The serum leptin level of breast cancer patients before chemotherapy is higher than that after chemotherapy. The decrease of leptin after chemotherapy can predict the prognosis of breast cancer. The expression of Ki-67 is closely related to the classic prognosis index of breast cancer, which is of great significance for the evaluation of neoadjuvant chemotherapy effect and clinical prognosis. However, the correlation between Leptin and Ki-67 in neoadjuvant chemotherapy of patients with locally advanced breast cancer (LABC) is rare. This paper mainly reviews the role of Leptin and Ki-67 in neoadjuvant chemotherapy of LABC.